DelveInsight’s “End-stage Renal Disease Pipeline Insight 2026” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the End-stage Renal Disease pipeline landscape. It covers the End-stage Renal Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the End-stage Renal Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the End-stage Renal Disease Pipeline? @ End-stage Renal Disease Pipeline Outlook Report

Key Takeaways from the End-stage Renal Disease Pipeline Report

• In March 2026- Iperboreal Pharma Srl initiated a study is open-label with blinded evaluator (primary endpoint), without blinding of patients or clinical staff. Patients should be enrolled if they are receiving 1, 2 or 3 diurnal exchanges of one of the following PD solutions (standard treatment): Physioneal 35 or 40 (including Clear-Flex bag), Fixioneal 35 or 40, Dianeal or Dianeal Low Calcium (1.36%, 2.27% or 3.86% glucose), or Balance, Bicavera, Bicanova or Equibalance (1.5%, 2.3%, 4.25% glucose) – and – one bag of Extraneal (7.5% Icodextrin) for the long-dwell exchange.
• In February 2026- Merck Sharp & Dohme LLC announced a phase 2 study is to evaluate the efficacy and safety of two different doses of MK-2060 (a monoclonal antibody against Factor XI) in end stage renal disease (ESRD) participants receiving hemodialysis via an arteriovenous graft (AVG). Data from this study will be used to aid dose selection of MK-2060 in future studies. The primary hypothesis is that at least one of the MK-2060 doses is superior to placebo in increasing the time to first occurrence of AVG event.
• DelveInsight’s End-stage Renal Disease Pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for End-stage Renal Disease treatment.
• The leading End-stage Renal Disease Companies, such as Aronora, Resverlogix Corporation, Vascular Therapies and others.
• Promising End-stage Renal Disease Therapies such as Zepatier, Mavyret, Epclusa, Empagliflozin 10 MG, Aranesp®, AMG 073 and others.

Want to know which companies are leading innovation in End-stage Renal Disease? @ End-stage Renal Disease Clinical Trials Assessment

The End-stage Renal Disease Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The End-stage Renal Disease Pipeline Report also highlights the unmet needs with respect to the End-stage Renal Disease.

End-stage Renal Disease Overview

End-stage renal disease (ESRD) is a severe and irreversible decline in kidney function that is fatal without dialysis or transplantation. It is characterized by a glomerular filtration rate (GFR) of less than 15 mL per minute per 1.73 m² body surface area, which is significantly lower than the typical kidney function of 90 mL per minute per 1.73 m². ESRD is a common complication of chronic kidney disease (CKD), which can be caused by various factors such as advanced age, hypertension, diabetes mellitus, obesity, a history of renal disease, and substance abuse like tobacco, heroin, or analgesics. The condition is associated with a range of maladaptive changes, including fluid retention, anaemia, disturbances of bone and mineral metabolism, dyslipidaemia, and protein energy malnutrition, which can contribute to increased cardiovascular risk and mortality.

End-stage Renal Disease Emerging Drugs Profile

• AB002: Aronora

The company’s lead product candidate, AB002 (E-WE thrombin), is a first-in-class protein C activator enzyme. AB002 has been designed to act in part by increasing the surface concentration of the anticoagulant, profibrinolytic, and cytoprotective enzyme, endogenous activated protein C (APC), at the site of developing blood clots via targeted cellular delivery. This unique mechanism of action allows AB002 to target cell-rich pathological blood clots (thrombi) without disabling vital hemostasis. AB002 received FDA Fast Track designation. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with End-Stage Renal Disease.

• Apabetalone: Resverlogix Corporation

Apabetalone (RVX-208), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease by regulating the expression of disease-causing genes. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with End-Stage Renal Disease.

If you’re tracking ongoing End-stage Renal Disease Clinical trials, this press release is a must-read @ End-stage Renal Disease Treatment Drugs

The End-stage Renal Disease Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of End-stage Renal Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for End-stage Renal Disease Treatment.
• End-stage Renal Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• End-stage Renal Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the End-stage Renal Disease market.

End-stage Renal Disease Companies

Aronora, Resverlogix Corporation, Vascular Therapies and others.

End-stage Renal Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

End-stage Renal Disease Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

From emerging drug candidates to competitive intelligence, the End-stage Renal Disease Pipeline Report @ End-stage Renal Disease Market Drivers and Barriers, and Future Perspectives

Scope of the End-stage Renal Disease Pipeline Report

• Coverage- Global
• End-stage Renal Disease Companies- Aronora, Resverlogix Corporation, Vascular Therapies and others.
• Promising End-stage Renal Disease Therapies- Zepatier, Mavyret, Epclusa, Empagliflozin 10 MG, Aranesp®, AMG 073 and others.
• End-stage Renal Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• End-stage Renal Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the End-stage Renal Disease Treatment landscape in this detailed analysis @ End-stage Renal Disease Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. End-stage Renal Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. End-stage Renal Disease – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. End-stage Renal Disease Collaboration Deals
9. Mid Stage Products (Phase II)
10. AB002: Aronora
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. Drug profiles in the detailed report…..
14. Pre-clinical and Discovery Stage Products
15. Drug profiles in the detailed report…..
16. Inactive Products
17. End-stage Renal Disease Key Companies
18. End-stage Renal Disease Key Products
19. End-stage Renal Disease- Unmet Needs
20. End-stage Renal Disease- Market Drivers and Barriers
21. End-stage Renal Disease- Future Perspectives and Conclusion
22. End-stage Renal Disease Analyst Views
23. End-stage Renal Disease Key Companies
24. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/end-stage-renal-disease-pipeline-insight